• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Fueling Cognitive Health through Nutrition & Supplementation

    2020 State of the Industry: High Expectations

    2020 International Buyers' Guide

    Clean Label Questions: Anything But ‘Short and Sweet’

    Key Trends in Functional Foods & Beverages for 2020
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Live From Shows
    Top News
    Pharmactive Affron Saffron May Help Relieve Depression Symptoms

    Warmer Temperatures Could Lead to Concerning Levels of Arsenic in Rice

    Kaneka Extends Deadline for Innovation Contest

    Maternal 5-MTHF Levels Predict Fetal Folate Status

    GOED Publishes 2017-2018 Omega-3 Raw Materials Report
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Pharmactive Affron Saffron May Help Relieve Depression Symptoms

    Kaneka Extends Deadline for Innovation Contest

    Maternal 5-MTHF Levels Predict Fetal Folate Status

    GOED Publishes 2017-2018 Omega-3 Raw Materials Report

    Probiotic Strain Shown to Reduce Symptoms of Infant Colic
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Pharmactive Affron Saffron May Help Relieve Depression Symptoms

    Warmer Temperatures Could Lead to Concerning Levels of Arsenic in Rice

    Maternal 5-MTHF Levels Predict Fetal Folate Status

    GOED Publishes 2017-2018 Omega-3 Raw Materials Report

    Obesity and Gum Disease May Have Common Connection: Inflammation
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Pharmactive Affron Saffron May Help Relieve Depression Symptoms

    Maternal 5-MTHF Levels Predict Fetal Folate Status

    Obesity and Gum Disease May Have Common Connection: Inflammation

    Probiotic Strain Shown to Reduce Symptoms of Infant Colic

    Clinical Trial Confirms Joint Health Benefits of NEM Brand Eggshell Membrane in 7 Days
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    MitoCarn (Alfasigma)

    Barrington Nutritionals

    Sabinsa Corporation

    PLT Health Solutions

    ExcelVite Sdn. Bhd.
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Aiya America (Matcha by Aiya)

    Bioenergy Life Science, Inc. (BLS)

    Barrington Nutritionals

    Sabinsa Corporation

    MitoCarn (Alfasigma)
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    CBD in the Clinic: How Practitioners View Life After the Farm Bill

    Holistic, functional medicine practitioners see therapeutic value of CBD and have confidence in its efficacy for a range of common health concerns.

    CBD in the Clinic: How Practitioners View Life After the Farm Bill
    Related CONTENT
    • FDA to Hold Public Meeting on ‘Responsible Innovation in Dietary Supplements’
    • FDA Launches Dietary Supplement Ingredient Advisory List
    • Follow the Science
    • Engaging Doctors in the Dialogue About ‘DSHEA 2.0’
    • ‘Can I Get Liability Insurance for My ‘Illegal’ CBD Products?
    By Erik Goldman, Holistic Primary Care10.07.19
    Passage of the Farm Bill of 2018, and the concurrent FDA approval of Epidiolex—the first prescription drug derived from Cannabis sativa—were landmarks in the evolution of the market for cannabis and its popular derivative, cannabidiol (CBD).

    How are medical practitioners responding to these seismic changes? In Holistic Primary Care’s 2019 practitioner survey, we sought to find out.

    The survey—fielded last spring—included a suite of questions about CBD, cannabis, and hemp, and generated responses from 360 clinicians.

    Not surprisingly, the data indicated that CBD is very much a part of routine clinical practice in the world of holistic medicine, and that practitioners generally view it as effective.

    However, many expressed concerns about the influx of poorly made, spiked, or fraudulent products now flooding the market.

    At the same time, they’re also wary of the machinations of the pharmaceutical industry as it tries to stake its claims on cannabis therapeutics.

    A few quick demographics on the survey’s respondents: 32% are medical doctors, 15% are naturopaths, another 10% are osteopaths, 9% are nurses, and 7% are chiropractors. The remainder represented a wide range of practitioner sub-types, including acupuncturists, pharmacists, nutritionists, health coaches, and homeopaths.

    Nearly 70% are women, and the majority are in solo (49%) or small group (20%) practice settings.

    Nearly all (95%) take supplements and natural products for their own health, and 65% dispense products in their offices.

    Enthusiasm for CBD
    More than half of these practitioners—54% to be exact—currently recommend non-prescription CBD-containing products to their patients.

    Another 17% are using both prescription (Epidiolex) and non-prescription forms of CBD. However, none of our respondents are recommending prescription Epidiolex exclusively.

    An additional 15% indicated that while they are not currently recommending CBD to patients, they are considering it; 14% are not currently recommending and have no plans to do so.

    Notably, the conventionally-trained MDs in our cohort tracked very closely with the cohort as a whole in terms of their attitudes toward CBD.

    The top 10 conditions or disorders for which our practitioners are recommending CBD are as follows: chronic pain (86%); stress/anxiety (82%); insomnia/sleep problems (82%); low back pain (58%); headache (45%); depression (32%); GI problems (31%); menopausal Sx (22%); menstrual Sx (22%); multiple sclerosis (21%).

    Overall, they indicated that they find non-Rx CBD products to be effective for stress/anxiety (96%); insomnia & sleep problems (94%); chronic pain (94%); and headache (85%).

    The FDA’s approval of Epidiolex has had limited impact on our respondents’ views about the medical benefits of cannabis-based treatments. But that’s largely because most of them were already onboard with CBD and cannabis long before it became a pharmaceutical.

    More than two-thirds (69%) said they were already convinced of the therapeutic value of cannabis compounds prior to the approval of Epidiolex. Another 16% stated that while the approval did not thoroughly convince them of CBD’s medical value, they are now more willing to look at clinical research on CBD and other cannabinoids.

    And 13% said that approval of Epidiolex has made them more open to the medical value of cannabis.

    Impact of the Farm Bill
    Likewise, the 2018 Farm Bill—an historic piece of legislation widely lauded by industry as a legitimizing moment—has had limited, though significant, impact on holistic practitioners.

    More than half (52%) said they were already recommending hemp-derived medicines prior to passage of the Farm Bill last December. Another 24% indicated that the new law makes them more willing to recommend these products. In contrast, only 2% said they are less willing to recommend hemp products. Eighteen percent had no opinion about the Farm Bill.

    Given that HPC’s respondents are strongly self-identified as “holistic” or “functional” medicine practitioners, it’s not surprising that so many are already utilizing CBD in their clinics, or that the Epidiolex approval and the Farm Bill had limited impact on their attitudes.

    For the majority of our audience, cannabis and cannabis-derived substances needed no legitimization from governmental agencies. A cohort of more conservative mainstream doctors would probably have shown a different response pattern.

    Verbatim comments from our survey contained some valuable signals about the subtle but important ways the federal government’s moves are impacting day-to-day practice.

    One respondent wrote: “I was recommending (CBD) before. Since the passage of the Farm Bill I’m more comfortable carrying products in office.”

    Another suggested that the Farm Bill’s biggest impact may be on patients who’ve been curious but reluctant to try CBD.

    “The trickle-down effect is slow. I still have patients ‘fearful’ of hemp-based products, or working under government contracts prohibiting the use of any and all hemp-based products.”

    One thing is certain: our practitioners want more information about cannabis and CBD. This topic is tied with the microbiome for first place among subjects about which our readers most want to learn.

    Nearly two thirds (62%) of respondents indicated a desire for greater coverage of cannabis and CBD in Holistic Primary Care.

    Concerns About Over-Hype
    While our respondents generally view CBD as reliable and effective, some voiced a concern that the benefits are being over-hyped.

    “I am concerned Cannabis has been touted as a panacea. I’m sure it has benefits or it wouldn’t have been used for so many years. However, there are side effects and risks to everything, and these are not being considered or publicized carefully enough,” wrote one practitioner.

    Several others called for more research to substantiate the bold disease treatment and prevention claims or insinuations that have become prevalent in the marketplace, despite very clear FDA prohibitions against making such claims.

    There are other issues beyond product quality, unsubstantiated claims, and the potential for direct cannabis-associated adverse effects. One respondent pointed out that chronic, long-term use of CBD or other hemp-based substances may confound a practitioner’s ability to figure out what’s going on with a particular patient.

    “I find that the use of these products may obscure other clinical signs and progress, and interfere sometimes with the homeopathic medicines and the assessment of the response to them.”

    Wary of Big Pharma
    Many holistic practitioners—like many of their patients—are wary of the pharmaceutical industry. The Epidiolex approval struck many survey respondents as a brazen move on the part of Big Pharma to exploit an herb that it once vilified.

    A number of respondents voiced concern that the pharmaceutical-ization of cannabis will lead to higher prices, restriction of access, and ultimately exclusion of people who would potentially benefit from CBD and other cannabinoids.

    “Epidiolex is the pharma mafia’s fractionalized version of cannabis. What families with kids with epilepsy can afford $32,000 year and no insurance covering it? It is pure greed on big pharma’s part,” wrote one practitioner. “Cannabis is a vegetable and people should be able to grow their own!”

    There’s mistrust of the supplement industry as well. One respondent noted: “I am just as skeptical of nutraceutical companies as pharmaceutical companies. At least pharma has some regulation.”

    Isolates vs ‘Full Spectrum’
    Though the survey did not specifically include questions about preferences for CBD isolates compared to “full-spectrum” hemp oils, it is clear that this distinction is known to practitioners, and on the minds of some.

    “I think Epidiolex as a single CBD compound is Big Pharma’s way of getting in the Cannabis market and ignores the power of whole plant therapy.”

    But the reality is that, at this point in time, terms like “full-spectrum” and “whole-plant” are marketing language, not scientific definitions. No regulatory agency has published an official definition of “full spectrum” hemp.

    There’s a vague consensus within the supplement industry that the term signifies an extract of hemp leaves (not seeds) that contains a number of other naturally occurring cannabinoids in addition to CBD, but minimal levels of THC. But there’s no clear definition about which cannabinoids must be present in the “full spectrum” and in what quantity.

    Anthony Almada, a nutrition industry consultant who heads IMAGINutrition, noted that cannabis produces more than 1,000 unique chemicals, with more still to be characterized. Validated analytical methods have yet to be defined for most of the constituents of this plant.

    At most, the “full-spectrum” products currently on the market are testing for 30-40 chemical constituents.

    “They’re ‘full-spectrum’ by virtue of the limitations on what’s being tested,” Almada said at Holistic Primary Care’s 7th annual Practitioner Channel Forum.

    He likened hemp to wine grapes: one can predict the general chemical profile of a certain type of grape, but this profile changes depending on cultivation region, soil, weather conditions, harvesting and handling. The same is true for hemp, and really, for all herbs.

    This is one of the major distinctions between minimally processed herbal extracts, and highly purified single-constituent pharmaceuticals. Given the current state of regulations, CBD products blur that line: there’s the highly-purified prescription drug form (Epidiolex), and there are hundreds of products being sold as full-spectrum “CBD hemp oil” or variations of that wording.

    To varying degrees, CBD companies are insinuating therapeutic equivalence between their products and the prescription drug form. They often cite studies done with Epidiolex or other CBD isolates, to support their proposed benefits.

    Practitioners—especially those who have a lot of experience with cannabis—are aware of these distinctions. But their patients often are not, and this puts them in the position of having to educate their patients, and help them to separate the true signals from the noise.

    In general, Holistic Primary Care’s practitioner audience sees value in non-prescription CBD as a therapeutic tool. They have confidence in its efficacy for a range of common health concerns. It is up to the industry to continue earning that confidence, and to ensure that it is not betrayed. 


    Erik Goldman
    Holistic Primary Care

    Erik Goldman is co-founder and editor of Holistic Primary Care: News for Health & Healing, a quarterly medical publication reaching about 60,000 physicians and other healthcare professionals nationwide. He is also co-producer of the Practitioner Channel Forum, the nation’s leading conference focused on opportunities and challenges in the practitioner segment of the dietary supplement industry. 
    Related Searches
    • Research
    • Herb
    • fda
    • Analytical
    Related Knowledge Center
    • Healthcare Trends
    • Herbs & Botanicals
    • Dietary Supplements
    Suggested For You
    CRN: Clear Legal Plan & FDA Enforcement Can Ensure Safety & Benefits of CBD CRN: Clear Legal Plan & FDA Enforcement Can Ensure Safety & Benefits of CBD
    Coalition Advocates for Declassification of Coconut as a ‘Tree Nut’ Allergen Coalition Advocates for Declassification of Coconut as a ‘Tree Nut’ Allergen
    Clinical Nutrition: A New Market Opportunity Clinical Nutrition: A New Market Opportunity
    CBD Regulatory Status Update: The Chaos Continues CBD Regulatory Status Update: The Chaos Continues
    Clearing Up Chaos in the Modern Nutraceuticals Market Clearing Up Chaos in the Modern Nutraceuticals Market
    The CBD Craze: Still Only the Beginning The CBD Craze: Still Only the Beginning
    Cannovia: Clearing Up CBD Market Confusion Cannovia: Clearing Up CBD Market Confusion
    Area Code 420 Has Arrived Area Code 420 Has Arrived
    Charlotte’s Web Introduces Hemp Extract-Infused Gummies Charlotte’s Web Introduces Hemp Extract-Infused Gummies
    EAS Assists Food & Hemp Firms with GRAS Submissions EAS Assists Food & Hemp Firms with GRAS Submissions
    Levagen PEA: A Legal Answer to CBD’s Issues Levagen PEA: A Legal Answer to CBD’s Issues
    Move Over Mainstream, Healthy Foods Are Here to Stay Move Over Mainstream, Healthy Foods Are Here to Stay
    Gencor Partners with Cannabis Researcher to Promote CBD Alternatives Gencor Partners with Cannabis Researcher to Promote CBD Alternatives
    BLIS M18 Probiotic Granted GRAS ‘No Objection’ Status BLIS M18 Probiotic Granted GRAS ‘No Objection’ Status
    OptiPEA Offers an Alternative to ‘Problem Child’ CBD OptiPEA Offers an Alternative to ‘Problem Child’ CBD

    Related Columns

    • Dietary Supplements | Healthcare Trends | Medical Nutrition | Quality & Safety | Regulations | Testing
      Developing Scientific Support for Product Claims

      Developing Scientific Support for Product Claims

      Generally accepted scientific principles should be used to determine the quality of studies used as evidence to substantiate a claim.
      By Greg Stephens, Windrose Partners & Sanford W. Bigelow, PhD, DABT, Vanguard Global Associates LLC 11.05.19

    • Dietary Supplements | Herbs & Botanicals | Natural/Organic | Quality & Safety | Regulations | Testing
      The Wild West Sells More than Just CBD

      The Wild West Sells More than Just CBD

      Self-determined GRAS is not a cure-all for NDINs, so be responsible and conduct the necessary safety and toxicology work.
      By Todd Harrison, Venable 11.05.19

    • Regulations | World Markets
      Regulatory Harmonization in Europe: Setting Daily Reference Values

      Regulatory Harmonization in Europe: Setting Daily Reference Values

      Maximum intake amounts of many micronutrients are still not regulated throughout the EU.
      By Joerg Gruenwald, analyze & realize ag 11.05.19


    • Dietary Supplements | Healthcare Trends | Herbs & Botanicals | Quality & Safety | Research | Testing
      Botanical Science: Post-Exercise Benefits & Neuroprotective Potential

      Botanical Science: Post-Exercise Benefits & Neuroprotective Potential

      AHPA compiles recent research on botanicals and plant compounds published in peer-reviewed journals.
      By Holly Johnson, PhD, American Herbal Products Association (AHPA) 11.05.19

    • Dietary Supplements | Healthcare Trends | Herbs & Botanicals | Quality & Safety | Regulations
      CBD Insurance: ‘The Perfume of the Premium’ Strengthens

      CBD Insurance: ‘The Perfume of the Premium’ Strengthens

      The insurance marketplace for hemp growers and CBD manufacturers will continue to expand.
      By Sheldon Baker, Baker Dillon Group LLC 10.07.19

    • Antioxidants | Dietary Supplements | Digestive Health | Herbs & Botanicals | Minerals | Research | Vitamins
      Cinnamon: A Journey from Traditional Flavor to Modern Health Applications

      Cinnamon: A Journey from Traditional Flavor to Modern Health Applications

      A remedy for many ailments in Ayurvedic medicine, science continues to uncover new uses for this common flavoring agent.
      By Dilip Ghosh, PhD, FACN, nutriConnect 10.07.19


    • Dietary Supplements | Healthcare Trends | Quality & Safety | Regulations
      Clinical Nutrition: A New Market Opportunity

      Clinical Nutrition: A New Market Opportunity

      Clearer language and scientific documentation for product benefits could open new doors for nutraceuticals in healthcare settings.
      By Greg Stephens, Windrose Partners, & Sheila Campbell, PhD, RD 09.09.19

    • Dietary Supplements | Herbs & Botanicals | Quality & Safety | Regulations
      CBD Regulatory Status Update: The Chaos Continues

      CBD Regulatory Status Update: The Chaos Continues

      FDA already has the authority to create a legal pathway for cannabidiol. It just needs the will to implement it.
      By Todd Harrison, Venable 09.09.19

    • Dietary Supplements | Healthcare Trends | Herbs & Botanicals | Regulations | World Markets
      Regulatory Harmonization in Europe: CBD Case Study

      Regulatory Harmonization in Europe: CBD Case Study

      Despite long-standing efforts, many EU regulatory standards are still out of alignment.
      By Joerg Gruenwald, analyze & realize ag 09.09.19


    • Delivery & Dosage Technologies | Diabetes & Blood Sugar Management | Herbs & Botanicals | Inflammation | Research | Weight Management/Weight Loss | Women's Health
      Botanical Science: Herbal Tea  Benefits, Amla for Metabolic Syndrome, Aronia for Inflammation

      Botanical Science: Herbal Tea Benefits, Amla for Metabolic Syndrome, Aronia for Inflammation

      AHPA compiles recent research on botanicals and plant compounds published in peer-reviewed journals.
      By Holly Johnson, PhD, American Herbal Products Association (AHPA) 09.09.19

    • Herbs & Botanicals | Quality & Safety | Regulations | Testing
      Mile High Labs: Stephen Mueller & The Mile High Monster

      Mile High Labs: Stephen Mueller & The Mile High Monster

      As chief technology officer and founder, he is the technical visionary of Mile High Labs and is designing/building and operating the future of hemp extraction.
      By Sheldon Baker, Baker Dillon Group LLC 07.03.19

    • Dietary Supplements | Regulations | World Markets
      Australia: Leading Regulation of Complementary Medicines

      Australia: Leading Regulation of Complementary Medicines

      The TGA recently implemented a Compliance Rating Scheme for listed medicines.
      By Dilip Ghosh, PhD, FACN, nutriConnect 07.03.19

    • Herbs & Botanicals
      Area Code 420 Has Arrived

      Area Code 420 Has Arrived

      Introducing Nutraceuticals World’s new Q&A column featuring entrepreneurs in the CBD, cannabis, hemp, and cannabinoid markets.
      By Sheldon Baker, Baker Dillon Group LLC 07.03.19

    • Dietary Supplements | Regulations
      DSHEA Discussion: Assessing Standards for Scientific Evidence

      DSHEA Discussion: Assessing Standards for Scientific Evidence

      Adjusting the health claims system could encourage more clinical trials and benefit consumers.
      By Todd Harrison, Venable 06.03.19

    • Dietary Supplements | Regulations | World Markets
      Non-Specific Health Claims: Beyond the Letter of the Law

      Non-Specific Health Claims: Beyond the Letter of the Law

      These statements are acceptable as long as they are either accepted generic descriptors or accompanied by a specific health claim.
      By Joerg Gruenwald, analyze & realize ag 06.03.19

    Breaking News
    • International Scientific Society Calls for Omega-3 Blood Testing in Future Research
    • Pharmactive Affron Saffron May Help Relieve Depression Symptoms
    • Warmer Temperatures Could Lead to Concerning Levels of Arsenic in Rice
    • Kaneka Extends Deadline for Innovation Contest
    • Maternal 5-MTHF Levels Predict Fetal Folate Status
    View Breaking News >
    CURRENT ISSUE

    December 2019

    • 2020 International Buyers' Guide
    • 2020 State of the Industry: High Expectations
    • Fueling Cognitive Health through Nutrition & Supplementation
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    International Scientific Society Calls for Omega-3 Blood Testing in Future Research
    Pharmactive Affron Saffron May Help Relieve Depression Symptoms
    Warmer Temperatures Could Lead to Concerning Levels of Arsenic in Rice
    Coatings World

    Latest Breaking News From Coatings World

    Cristo Rey High School Educator Named 2019 Axalta All-Pro Teacher of the Year
    Michelman Makes United Way of Greater Cincinnati’s List of Top 25 Corporate Campaigns
    BCF: Coatings Industry Reports Record Improvement in Waste, Recycling, Accident Rates
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs Roche's Nasal Swab MRSA Test
    Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs
    Eye Test for Parkinson's Gains Breakthrough Designation
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Almac Awarded $1M BMGF Grant
    Vivera Pharma, Parexel Ink Clinical Services Agreement
    MedPharm Triples Capacity at RTP Site
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    WWP Wins Three NJPEC Awards
    Cat-Themed Beauty Collection to Launch in Japan
    Pantone Names Classic Blue the 2020 Color of the Year
    Happi

    Latest Breaking News From Happi

    Lip Lab Opening in Brooklyn
    Raining Rose Expands Exec Team
    Scott’s Sells Personal Care Production Site
    Ink World

    Latest Breaking News From Ink World

    ePac Flexible Packaging Expands into Asia Pacific Market
    Haney, HP Developing Sustainable Fashion Packaging for Heron Preston
    Addipel Moves to New HQ, Expands Production Facility
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    HP teams with Haney for sustainable packaging
    Tags & Labels Printing adds Heidelberg’s Versafire EP
    Austrian converter installs first Nilpeter press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Thrace to Relocate U.S. Capacity
    FiltXPO Speaker Line-Up Announced
    Nölken Incorporates Sustainable Wipes Packaging
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Appoints New Spine Business Leader
    Viant to Halt EtO Sterilization at Michigan Plant by End of Year
    Synaptive Medical's Modus V Expands Into Spine Market
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    IDTechEx Show! Announces Graphene Award Winner
    OE-A Continues to Bring Future of Printed Electronics to CES 2020
    Avancis, Smit Thermal, HZB, CNRS, Solliace Team for Higher Efficiencies in CIGS

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.